Application of multiprobe fluorescence in situ hybridization panel in the diagnosis of acute myeloid leukemia.
- Author:
Lu-Lu XU
1
;
Xiao-Li LIU
;
Qing-Feng DU
;
Lan-Lin SONG
;
Rui CAO
;
Na XU
;
Jin-Fang ZHANG
;
Bin-Tao HUANG
;
Xu-Jing LUO
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; DNA Probes; Female; Humans; In Situ Hybridization, Fluorescence; methods; Leukemia, Myeloid, Acute; diagnosis; Male; Middle Aged; Young Adult
- From: Journal of Southern Medical University 2011;31(7):1204-1206
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo assess the value of multiprobe fluorescence in situ hybridization (FISH) panel in the diagnosis of acute myeloid leukemia (AML).
METHODSThe multiprobe AML/MDS panel comprising 8 different FISH probes for AML1/ETO transfusion gene, PML-RARα transfusion gene, CBFβ/MYH11 transfusion gene, MLL breakapart, P53 deletion, Del(5q), -7/Del(7q), and Del(20q) was tested in 40 cases of AML, and the results were compared with those by conventional cytogenetic G-banding (CCG) test.
RESULTSWith multiprobe FISH panel, 22 of the 40 AML cases were found to carry 7 types of cytogenetic abnormalities, namely AML1/ETO transfusion gene, PML-RARα transfusion gene, MLL breakapart, P53 deletion, Del(5q), -7/Del(7q) and trisomy 8. The positive ratio of the multiprobe FISH was 57.5%. CCG only identified 8 cases with the corresponding cytogenetic abnormalities and 3 cases with other cytogenetic abnormalities, and the positive ratio was only 27.50%.
CONCLUSIONMutiprobe FISH panel is more rapid, accurate and effective than CCG in the diagnosis of AML.
